Digital PCR for BCR-ABL1 Quantification in CML: Current Applications in Clinical Practice

Area of Science:

• Hematology
• Molecular Biology
• Medical Diagnostics

Background:

• Accurate monitoring of BCR-ABL1 transcript levels is crucial for managing chronic myeloid leukemia (CML).
• Current real-time quantitative PCR (qPCR) methods have limitations in quantification accuracy and sensitivity for residual disease.
• Precise BCR-ABL1 measurements are essential for treatment response milestones and tyrosine kinase inhibitor (TKI) discontinuation decisions.

Purpose of the Study:

• To review the application of digital PCR (dPCR) for monitoring CML treatment response.
• To evaluate dPCR's potential as an alternative to qPCR for BCR-ABL1 quantification.
• To assess dPCR's utility in identifying patients eligible for TKI discontinuation.

Main Methods:

• Review of current literature on digital PCR (dPCR) for BCR-ABL1 monitoring in CML.
• Comparison of dPCR's precision and sensitivity against traditional qPCR methods.
• Analysis of dPCR's role as a prognostic marker for TKI treatment discontinuation.

Main Results:

• dPCR provides absolute quantification of BCR-ABL1 transcripts with high precision across various disease levels.
• dPCR demonstrates clinical sensitivity down to MR5.0, surpassing qPCR's limitations in deep molecular response.
• dPCR has been validated as a prognostic marker for successful TKI treatment discontinuation, unlike qPCR.

Conclusions:

• dPCR is a promising, highly precise, and sensitive method for molecular monitoring in CML.
• dPCR can reliably identify patients achieving treatment milestones and those suitable for TKI discontinuation.
• dPCR may become the preferred method for CML response monitoring and guiding TKI therapy cessation.